
























Inhaler Coverage Updates

Generic Name <i>Trade Name</i> Dosage Forms and Strength Number of Doses	Device	Dose Counter / Daily Dosing	PharmaCare Coverage Cost per inhaler (after deductible) <i>*Cost are an approximation</i>	Comments
Sort Acting Beta ₂ Agonist (SABA)				
Salbutamol <i>Ventolin®</i> , <i>Airomir®</i> MDI: 100 mcg/puff 200 puffs		- / -	Regular Benefit \$20/inhaler (\$5)	
<i>Ventolin Diskus®</i> Diskus: 200 mcg/inhalation 60 doses		✓ / -	Non-Benefit \$25/inhaler	
Terbutaline <i>Bricanyl Turbuhaler®</i> DPI: 500 mcg/inhalation 200 doses		✓ / -	Regular Benefit \$25/inhaler (\$10)	
Sort Acting Muscarinic Antagonist (SAMA)				
Ipratropium bromide <i>Atrovent®</i> MDI: 20 mcg/puff 200 puffs		- / -	Regular Benefit \$35/inhaler (\$10)	
Combination: SABA and SAMA				
Ipratropium + salbutamol <i>Combivent Respimat®</i> Respimat: 20/100 mcg per actuation 120 actuations		✓ / -	Regular Benefit \$50/inhaler (\$15)	
Long-Acting Muscarinic Antagonist (LAMA)				
Tiotropium bromide <i>Spiriva Respimat®</i> Respimat: 2.5 mcg/actuation 60 actuations		✓ / ✓	Regular Benefit \$75/inhaler (\$20)	¹ Special authority criteria: failed trial of EACH regular benefit LAMA.
<i>Spiriva HandiHaler®</i> Handihaler: 18 mcg/inhalation 30 capsules		✓ / ✓	Limited Coverage – Special Authority¹ \$75/inhaler (\$20)	
Umeclidinium bromide <i>Incruse Ellipta®</i> DPI: 62.5 mcg/inhalation 30 doses		✓ / ✓	Regular Benefit \$70/inhaler (\$20)	
Acclidinium bromide <i>Tudorza Genuair®</i> DPI: 400 mcg/inhalation 60 doses		✓ / -	Limited Coverage – Special Authority¹ \$75/inhaler (\$60)	
Glycopyrronium bromide <i>Seebri Breezhaler®</i> DPI: 50 mcg/inhalation 30 capsules		✓ / ✓	Limited Coverage – Special Authority¹ \$75/inhaler (\$60)	
Long-Acting Beta ₂ Agonist (LABA)				
Formoterol <i>Foradil®</i> DPI: 12 mcg/inhalation 60 capsules		✓ / -	Limited Coverage – Special Authority² \$75/inhaler (\$60)	² Special authority criteria: diagnosis of asthma AND inadequate response

Indacaterol maleate <i>Onbrez Breezhaler</i> ® DPI: 75 mcg/inhalation 30 capsules		✓ / ✓	Limited Coverage – Special Authority³ \$90/inhaler (\$70)	on optimal dose of ICS. ³ Special authority criteria: diagnosis of COPD (FEV ₁ /FVC <0.70) AND contraindication or intolerance to LAMA AND dosage does not exceed 75 mcg/day.
Salmeterol <i>SereVent Diskus</i> ® Diskus: 50 mcg/inhalation 60 doses		✓ / -	Limited Coverage – Special Authority⁴ \$90/inhaler (\$70)	

Tiotropium/olodaterol <i>Inspiroto Respimat</i> ® Respimat: 2.5/2.5 mcg per actuation 60 actuations		✓ / ✓	Limited Coverage – Special Authority⁵ \$90/inhaler (\$70)	trial of either LAMA or LABA.
Umeclidinium/vilanterol <i>Anoro Ellipta</i> ® DPI: 62.5/25 mcg per inhalation 30 doses		✓ / ✓	Limited Coverage – Special Authority⁵ \$115/inhaler (\$95)	
Combination: LABA + ICS				
Budesonide/formoterol <i>Symbicort Turbuhaler</i> ® DPI: 200/6 mcg per inhalation 120 doses		✓ / -	Limited Coverage – Special Authority⁶ \$100/inhaler (\$90)	⁶ Special authority criteria: diagnosis of asthma AND inadequate response on optimal dose of ICS
Mometasone/formoterol <i>Zenhale</i> ® MDI: 100-200/5 mcg per puff 120 puffs		✓ / -	Limited Coverage – Special Authority⁶ \$125-150/inhaler (\$85-105)	
Fluticasone/salmeterol <i>Advair Diskus</i> ®, <i>Wixela</i> ® DPI: 100, 250 or 500/50 mcg per inhalation 60 inhalations		✓ / -	Limited Coverage – Special Authority⁷ \$60-100/inhaler (\$55-80)	⁷ Special authority criteria for asthma : inadequate response to optimal dose of ICS. Special authority criteria for COPD : FEV ₁ /FVC <0.7 AND post-bronchodilator FEV ₁ < 80% AND [history of ≥2 moderate exacerbations requiring antibiotics or glucocorticoids in previous 12 months OR history of ≥1 severe exacerbation requiring hospital admission in last 12 months] AND inadequate response to minimum 6-month trial of LAMA or LABA.
Advair MDI ® MDI:125 or 250/50 mcg per puff 120 inhalations		✓ / -	Limited Coverage – Special Authority⁷ \$140-195/inhaler (\$105-150)	
Fluticasone/vilanterol <i>Breo Ellipta</i> ® DPI: 100/25 mcg per inhalation 30 doses		✓ / ✓	Limited Coverage – Special Authority⁷ \$120-180/inhaler (\$100-130)	
Combination: LAMA, LABA and ICS				
Umeclidinium/vilanterol/ fluticasone <i>Trelegy Ellipta</i> ® DPI: 62.5/25/100 mcg per inhalation 30 doses		✓ / ✓	Limited Coverage – Special Authority⁸ \$175/inhaler (\$145)	⁸ Special authority criteria for COPD : FEV ₁ /FVC <0.7 AND post-bronchodilator FEV ₁ < 80% AND [history of ≥2 moderate exacerbations requiring antibiotics or glucocorticoids in previous 12 months OR history of ≥1 severe exacerbation requiring hospital admission in last 12 months] AND inadequate response to minimum 6-month trial of either [LAMA or LABA OR ICS-LABA combination].
Glycopyrronium/formoterol/ budesonide <i>Breztri Aerosphere</i> ® MDI: 8.2/5.8/182 mcg per puff 120 puffs		✓ / -	Limited Coverage – Special Authority⁸ \$160/inhaler (\$110)	
Glycopyrronium/indacaterol/ mometasone <i>Energair Breezhaler</i> ® DPI: 50/150/160 mcg per inhalation 30 capsules		✓ / ✓	Limited Coverage – Special Authority⁹ \$130/inhaler (\$100)	⁹ Special authority criteria for asthma : inadequate response with optimal dose of

				LABA and moderate to high dose of ICS AND have experienced one or more asthma exacerbation in previous 12 months.
--	--	--	--	---

Plan W registrants do not have to pay any cost for regular benefit medications or medications with special authority approval.

Notes/Resources:






Spirometry: If no spirometry measurements on file, PharmaCare will provide a 6-month period of coverage during which spirometry results must be obtained and provided to continue coverage.

Inhaler Technique:

Patient resources for video demonstration: <https://www.lung.ca/lung-health/how-use-your-inhaler>

Patient resources with step-by-step instructions for use: <https://www.lungsask.ca/media/41> or <https://www.lungsask.ca/media/42>

“Hand versus Lung Approach”: recommendations for best device selection (Reference: RxFiles)

Inhaler	Best for Weak Hands?	Best for Weak Lungs?
Metered-dose Inhaler 		✓
Respimat 		✓
Breezhaler or Handihaler 		✓
Diskus, Ellipta or Turbuhaler 	✓	
Genuair 	✓	✓

Sustainability and Inhaler Prescribing:*CASCADES Initiative for Climate Conscious Prescribing:*

- CASCADES is working to create and promote sustainable healthcare systems. One current initiative is: The Climate Conscious Inhaler Prescribing Learning Collaborative. Resources for climate conscious inhaler prescribing are outlined below:
 - Infographic: <https://cascadescanada.ca/wp-content/uploads/2022/07/June-2022-Inhalers-Infographic-Updated.pdf>
 - Considerations for Climate Conscious Prescribing: <https://cascadescanada.ca/wp-content/uploads/2022/09/Sustainability-Pathway-and-Considerations-for-Climate-Conscious-Prescribing.pdf>